A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF)
What is the purpose of this trial?
The purpose of this study is to determine if Simtuzumab (GS-6624) is safe and effective in treating Idiopathic Pulmonary Fibrosis.
- 45 Years - 85 Years
- Gilead Sciences
- Last Updated:
- Study HIC#: